Stress-induced Sleep Deficits and a Complementary Therapy

NCT05280561 | Completed

• 1 other identifier: UP-21-00653
• Study Type: interventional
• Target: 288
• Locations: 1 country
• Sites: 1

Brief Summary

The COVID-19 pandemic and social isolation order induced stress/anxiety as well as cellphone dependence. As a result, sleep disruption and mental distress became major health concerns. Gamma-aminobutyric acid type-A receptor (GABAAR) is one of the key players in modulating sleep. Dihydromyricetin (DHM), an herbal compound, plays a role in GABAAR modulation and mitigating anxiety. The investigators' partner in China obtained 288 participants who completed the online survey to gain insight into how stress/anxiety and time spent on cellphones affected sleep and mood. The participants were then enrolled in a randomized placebo-controlled double-blind study to assess the effects of DHM on sleep and improvement on stress/anxiety and cellphone using time.

Conditions

Insomnia Due to Anxiety and Fear

Outcome Measures

Primary Outcomes (4)

• Effect of DHM on sleep duration

  Changes in hours of sleep reported as the difference between self-reported hours of sleep before and after DHM or placebo.

  20 days

• Effect of DHM on stress levels

  Changes in stress levels reported as the difference between self-reported stress levels before and after DHM or placebo. Stress levels were scaled from 0 to 10, with 10 being the highest stress level.

  20 days

• Effect of DHM on cellphone time

  Changes in hours spent on cellphone reported as the difference between self-reported cellphone usage before and after DHM or placebo.

  20 days

• Effect of DHM on feelings after waking up

  Changes in negative feelings after waking up, reported as the difference between the self-reported negative feelings before and after DHM or placebo. In the survey, "feelings after waking up" included negative feelings such as tense, lack of motivation, and irritable/angry. To quantify these feelings, a 'Yes' counted as -1 point, a 'No' counted as 0 points, and a 'Not sure' counted as -0.5 points. The sum of these scores were calculated as the total negative feeling after waking up. Lower score (more negative) indicated worse feelings.

  20 days

Study Arms (2)

DHM group

EXPERIMENTAL

This arm is to evaluate DHM effects on the intervention of stress-induced insomnia during the pandemic. DHM granular preparation contains DHM 200 mg plus same excipients as placebo. The 244 participants were taken DHM granular preparation, which was dissolved in \~100 ml water for oral administration, once daily for 20 days.

Dietary Supplement: DHM

Control group

PLACEBO COMPARATOR

The placebo contained excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g

Dietary Supplement: Placebo

Interventions

DHM DIETARY_SUPPLEMENT

DHM is a positive modulator of GABA. We hypothesize the DHM could reduce stress/anxiety induced insomnia during the pandemic

DHM group

Placebo DIETARY_SUPPLEMENT

Excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g

Control group

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy subjects were recruited in Chengdu and Beijing (city) in China,
• Able and willing to sign informed consent,
• Between 18 -60 years old at time of consent,
• No alcohol, drug, and smoking,
• Not using sleep medication(s) or other psychiatric medications.

You may not qualify if:

• Pregnant or Breastfeeding women,
• Currently taking any medications for sleep,
• Reported naps \> 3 times per week
• History of sleep apnea,
• Current alcohol, drug, and smoking

Sponsors & Collaborators

• University of Southern California: lead
• University of California, Los Angeles: collaborator

Study Sites (1)

Furise Group Co

Chengdu, Sichuan, China

Location

Related Publications (3)

• Shen Y, Lindemeyer AK, Gonzalez C, Shao XM, Spigelman I, Olsen RW, Liang J. Dihydromyricetin as a novel anti-alcohol intoxication medication. J Neurosci. 2012 Jan 4;32(1):390-401. doi: 10.1523/JNEUROSCI.4639-11.2012.

  PMID: 22219299 RESULT

• Liang J, Lopez-Valdes HE, Martinez-Coria H, Lindemeyer AK, Shen Y, Shao XM, Olsen RW. Dihydromyricetin ameliorates behavioral deficits and reverses neuropathology of transgenic mouse models of Alzheimer's disease. Neurochem Res. 2014 Jun;39(6):1171-81. doi: 10.1007/s11064-014-1304-4. Epub 2014 Apr 13.

  PMID: 24728903 RESULT

• Silva J, Shao AS, Shen Y, Davies DL, Olsen RW, Holschneider DP, Shao XM, Liang J. Modulation of Hippocampal GABAergic Neurotransmission and Gephyrin Levels by Dihydromyricetin Improves Anxiety. Front Pharmacol. 2020 Jul 9;11:1008. doi: 10.3389/fphar.2020.01008. eCollection 2020.

  PMID: 32742262 RESULT

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: 288 subjects were recruited for the study. The sample size was based on a prior power analyses using G-Power 3, for a Mixed Model Repeated Measures Analysis of Variance (MMRMA) design, assuming a statistical power of 0.8, moderate effects of the DHM effects on sleep outcomes, and hypothesis tests conducted at a probability value of .05.

Study Record Dates

• First Submitted: February 11, 2022
• First Posted: March 15, 2022
• Study Start: July 25, 2021
• Primary Completion: October 31, 2022
• Study Completion: November 3, 2022
• Last Updated: January 5, 2023

Record last verified: 2023-01

Locations

CN (1)